Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00061035 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Transgenic Lymphocyte Immunization Vaccine in Subjects With Prostate Adenocarcinoma
A Phase 1 study of Prostatic Neoplasms, sponsored by Cosmo Bioscience.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT00061035 is a Phase 1 study of Prostatic Neoplasms that has completed, run by Cosmo Bioscience. The registered enrollment target is 18 participants, below the 514-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00061035, a Phase 1 study of Prostatic Neoplasms, has completed, sponsored by Cosmo Bioscience.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
Dr. Frederick Millard, MD, Associate Clinical Professor at the UCSD Cancer Center, will be conducting a 12-week study in advanced prostate cancer patients. The study will be held at the UCSD Medical Center and will test an experimental investigational gene therapy vaccine designed to make the patient's immune system react against telomerase, an enzyme expressed in prostate cancer cells.
Conditions Studied
Interventions
- BIOLOGICAL Transgenic Lymphocyte Immunization Vaccine (TLI)
Study Locations (1)
California
- University of California, San Diego Cancer Center - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2003-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00061035
The ClinicalTrials.gov registry entry for NCT00061035 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 514-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (96% lower). The listed sponsor is Cosmo Bioscience, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostatic Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Transgenic Lymphocyte Immunization Vaccine (TLI) is the first listed.
NCT00061035 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00061035 about?
NCT00061035 is a clinical study titled "Evaluation of Transgenic Lymphocyte Immunization Vaccine in Subjects With Prostate Adenocarcinoma". Dr. Frederick Millard, MD, Associate Clinical Professor at the UCSD Cancer Center, will be conducting a 12-week study in advanced prostate cancer patients. The study will be held at the UCSD Medical Center and will test an experimental investigational gene therapy vaccine designed to make the patien...
What is the current status of trial NCT00061035?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2003-04.
What conditions does trial NCT00061035 study?
This clinical trial studies the following conditions: Prostatic Neoplasms.
What interventions are being tested in trial NCT00061035?
The interventions under investigation include: Transgenic Lymphocyte Immunization Vaccine (TLI) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00061035?
This trial is sponsored by Cosmo Bioscience, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00061035 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
-
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
RECRUITING · Phase 1
-
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
RECRUITING · Phase 1
-
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
RECRUITING · Phase 1
-
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
RECRUITING · Phase 1
-
A Study of DM002 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.